Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer.
Cancer
Diagnosis
PD-L1
Pathology
Triple-negative breast cancer
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
07 Oct 2023
07 Oct 2023
Historique:
received:
26
07
2023
accepted:
07
09
2023
medline:
7
10
2023
pubmed:
7
10
2023
entrez:
7
10
2023
Statut:
aheadofprint
Résumé
PD-L1 expression is known to predict the benefits of immune checkpoint inhibitor therapy for triple-negative breast cancer (TNBC). We examined whether the PD-L1 expression evaluated in biopsy specimens accurately reflects its expression in the whole tumor. Immunohistochemistry was performed on 81 biopsy and resection specimens from patients with TNBC to determine their PD-L1 status. We found PD-L1-positive tumors in 23 (28%) biopsy specimens and primarily PD-L1-negative tumors in 58 (72%). The PD-L1 status was reevaluated in matching postoperative specimens of primarily PD-L1-negative tumors. Of them, 31% (18/58) were positive, whereas 69% (40/58) were negative. Considering the pre- and postoperative analyses, 41 (51%) patients had PD-L1-positive tumors, while 40 had PD-L1-negative tumors. We found 18 (22%) more PD-L1-positive tumors while examining the resection specimens compared to biopsies, and the difference was statistically significant (p = 0.0038). Diagnostic biopsies do not fully reflect the PD-L1 expression in TNBC. Our results suggest that a significant subset of TNBC patients may be misclassified as PD-L1-negative and disqualified from anti-PD-L1 therapy.
Identifiants
pubmed: 37804360
doi: 10.1007/s10238-023-01190-2
pii: 10.1007/s10238-023-01190-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Yin L, Duan J-J, Bian X-W, Yu S-C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:61.
doi: 10.1186/s13058-020-01296-5
pubmed: 32517735
pmcid: 7285581
Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era. BMC Med. 2019;17:90.
doi: 10.1186/s12916-019-1326-5
pubmed: 31068190
pmcid: 6507064
Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15:121.
doi: 10.1186/s13045-022-01341-0
pubmed: 36038913
pmcid: 9422136
Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, Freeman GJ, Sharpe AH. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214:895–904.
doi: 10.1084/jem.20160801
pubmed: 28302645
pmcid: 5379970
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10:727–42.
pubmed: 32266087
pmcid: 7136921
Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.
doi: 10.3389/fphar.2017.00561
pubmed: 28878676
pmcid: 5572324
Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847–56.
doi: 10.1158/1535-7163.MCT-14-0983
pubmed: 25695955
Tsao MS, Kerr KM, Kockx M, Beasley M-B, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou T-Y, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018;13:1302–11.
doi: 10.1016/j.jtho.2018.05.013
pubmed: 29800747
pmcid: 8386299
Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M, Sommaggio M, Brunelli M, Martignoni G, Netto GJ, Hoque MO, et al. PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsy specimens and whole sections. J Thorac Oncol. 2018;13:1113–20.
doi: 10.1016/j.jtho.2018.04.017
pubmed: 29704674
Kim I, Kim A, Lee CH, Lee G, Kim A, Jo EJ, Kim M-H, Mok J, Lee K, Kim KU, et al. Reliability of PD-L1 assays using small tissue samples compared with surgical specimens. Medicine. 2019;98: e14972.
doi: 10.1097/MD.0000000000014972
pubmed: 30946323
pmcid: 6455756
Chen M, Xu Y, Zhao J, Li J, Liu X, Zhong W, Wang M. Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer. Thorac Cancer. 2021;12:2339–44.
doi: 10.1111/1759-7714.14075
pubmed: 34291566
pmcid: 8410567
Noske A, Steiger K, Ballke S, Kiechle M, Oettler D, Roth W, Weichert W. Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens. J Clin Pathol. 2023. https://doi.org/10.1136/jcp-2022-208637 .
doi: 10.1136/jcp-2022-208637
pubmed: 36669878
Dobritoiu F, Baltan A, Chefani A, Billingham K, Chenard M-P, Vaziri R, Lacroix-Triki M, Waydelich A, Erb G, Andersson E, et al. Tissue selection for PD-L1 testing in triple negative breast cancer (TNBC). Appl Immunohistochem Mol Morphol. 2022;30:549–56.
doi: 10.1097/PAI.0000000000001053
pubmed: 36036647
pmcid: 9444286
Ben Dori S, Aizic A, Zubkov A, Tsuriel S, Sabo E, Hershkovitz D. The risk of PD-L1 expression misclassification in triple-negative breast cancer. Breast Cancer Res Treat. 2022;194:297–305.
doi: 10.1007/s10549-022-06630-3
pubmed: 35622241
pmcid: 9239943
Baek SH, Kim JH, Bae SJ, Ji JH, Lee Y, Jeong J, Cha YJ, Ahn SG. SP142 PD-L1 assays in multiple samples from the same patients with early or advanced triple-negative breast cancer. Cancers. 2022. https://doi.org/10.3390/cancers14133042 .
doi: 10.3390/cancers14133042
pubmed: 36497457
pmcid: 9658191
Kahn AM, Golestani R, Harigopal M, Pusztai L. Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer. Breast Cancer Res Treat. 2023. https://doi.org/10.1007/s10549-023-06977-1 .
doi: 10.1007/s10549-023-06977-1
pubmed: 37378695
Paré L, Pascual T, Seguí E, Teixidó C, Gonzalez-Cao M, Galván P, Rodríguez A, González B, Cuatrecasas M, Pineda E, et al. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Ann Oncol. 2018;29:2121–8.
doi: 10.1093/annonc/mdy335
pubmed: 30165419
Teng F, Meng X, Kong L, Yu J. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: a systematic review. Cancer Lett. 2018;414:166–73.
doi: 10.1016/j.canlet.2017.11.014
pubmed: 29155348
Planes-Laine G, Rochigneux P, Bertucci F, Chrétien A-S, Viens P, Sabatier R, Gonçalves A. PD-1/PD-L1 targeting in breast cancer: the first clinical evidences are emerging. A literature review. Cancers. 2019;11:541. https://doi.org/10.3390/cancers11071033 .
doi: 10.3390/cancers11071033
Center for Drug Evaluation; Research FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer (accessed on 1 July 2023).
Center for Devices; Radiological Health List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools) Available online: https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools (accessed on 1 July 2023).
EMA Tecentriq Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq (accessed on 30 June 2023).
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32:994–1004.
doi: 10.1016/j.annonc.2021.05.801
pubmed: 34219000
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im S-A, Shaw Wright G, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21.
doi: 10.1056/NEJMoa1809615
pubmed: 30345906
Lee H-H, Wang Y-N, Xia W, Chen C-H, Rau K-M, Ye L, Wei Y, Chou C-K, Wang S-C, Yan M, et al. Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy. Cancer Cell. 2019;36:168-178.e4.
doi: 10.1016/j.ccell.2019.06.008
pubmed: 31327656
pmcid: 6793936
Bigras G, Mairs S, Swanson PE, Morel D, Lai R, Izevbaye I. Small biopsies misclassify up to 35% of PD-L1 assessments in advanced lung non-small cell lung carcinomas. Appl Immunohistochem Mol Morphol. 2018;26:701–8.
doi: 10.1097/PAI.0000000000000698
pubmed: 30095468